MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...
Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million.
Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires ...
Zacks Investment Research on MSN
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report third-quarter 2025 results on Oct. 30, before market ...
29 August 2024, Bavaria, Munich: The logo of the pharmaceutical company Bristol-Myers Squibb, (BMS) is seen on the facade of the company's Munich headquarters on August 29, 2024 in Munich (Bavaria).
The U.S. FDA's approval Thursday of Bristol Myers Squibb's (NYSE:BMY) novel antipsychotic Cobenfy (xanomeline and trospium chloride) for schizophrenia could significant influence treatment of the ...
Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive ...
On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...
We recently published Top 10 Trending Stocks Everyone’s Watching in Q4. Bristol-Myers Squibb Company (NYSE:BMY) is one of the trending stocks everyone’s watching. Morningstar’s Dave Sekera said in a ...
Bristol Myers BMY won FDA approval for xanomelineand trospiumchloride (formerly KarXT), an oral medication for the treatment of schizophrenia in adults, in September 2024. The drug was approved under ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Credit: Bristol Myers Squibb. Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors. Data from the EMERGENT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback